VacZine Analytics  
MarketVIEW: Helicobacter pylori vaccines

Published: December 2015

Helicobacter pylori is one of world’s most common infections with approximately half to two thirds of the world’s population harbouring the bacterium. H.pylori, which colonizes the human stomach mucosa, can cause active, chronic persistent and atrophic gastritis in adults and children. The bacterium causes more than 90% of duodenal ulcers and up to 80% of gastric cancers. Gastric cancer is the third most common cause of cancer-related deaths in the world, killing approximately 723,000 people in 2012.

H.pylori infection can be eradicated by use of antibiotics and proton-pump inhibitor (PPI) therapy. However, the therapy can be demanding in terms of patient compliance and its effectiveness is impacted by antibiotic resistance. Around 20% of patients fail first line therapy and re-infection is common. Importantly, individuals are only treated on presentation with symptoms because a population wide eradication program is unfeasible. Many investigators have attempted to develop both H.pylori therapeutic and prophylatic vaccines with little clinical success. However, an oral urease vaccine was approved in China in 2009 after showing efficacy in Phase III studies in children

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value H.pylori prophylatic and therapeutic vaccines across relevant markets to 2035. Each model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon the amount of countries targeted by a potential prophylatic vaccine. The therapeutic vaccine model focuses on new and ever (recurrent cases) of peptic ulcer disease.

THIS PRODUCT IS A EXECUTIVE PRESENTATION AND TWO FORECAST MODELS

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV065 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2015 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains